New drug duo aims to knock out hepatitis d virus
NCT ID NCT06903338
Summary
This Phase 3 trial is testing whether a combination of two drugs, tobevibart and elebsiran, can effectively treat chronic hepatitis D infection. It will compare people who receive the treatment right away to those whose treatment is delayed. The main goal is to see if the treatment can reduce the hepatitis D virus to undetectable levels and improve liver health after 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Chandler, Arizona, 85224, United States
-
Investigative Site
Los Angeles, California, 90033, United States
-
Investigative Site
Redwood City, California, 94063, United States
-
Investigative Site
San Francisco, California, 94143, United States
-
Investigative Site
DeLand, Florida, 32720, United States
-
Investigative Site
Chicago, Illinois, 60612, United States
-
Investigative Site
Baltimore, Maryland, 21287, United States
-
Investigative Site
Hillsborough, New Jersey, 08844, United States
-
Investigative Site
New York, New York, 10016, United States
-
Investigative Site
New York, New York, 10021, United States
-
Investigative Site
New York, New York, 10029, United States
-
Investigative Site
Murray, Utah, 84107, United States
-
Investigative Site
Seattle, Washington, 98105, United States
-
Investigative Site
Calgary, Alberta, T2N 4Z6, Canada
-
Investigative Site
Montreal, Quebec, H2L 4E9, Canada
-
Investigative Site
Montreal, H2X 1R9, Canada
-
Investigative Site
Ottawa, K1H8L6, Canada
-
Investigative Site
Québec, G1V 4G2, Canada
-
Investigative Site
Vancouver, V6Z 2C7, Canada
-
Investigative Site
Tbilisi, 0102, Georgia
-
Investigative Site
Tbilisi, 0114, Georgia
-
Investigative Site
Tbilisi, 0159, Georgia
-
Investigative Site
Frankfurt, 60590, Germany
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Heidelberg, 69120, Germany
-
Investigative Site
Chisinau, 2025, Moldova
-
Investigative Site
Auckland, 1010, New Zealand
-
Investigative Site
Karachi, 74800, Pakistan
-
Investigative Site
Karachi, 75600, Pakistan
-
Investigative Site
Lahore, 54800, Pakistan
-
Investigative Site
Rawalpindi, 46000, Pakistan
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Bucharest, 022328, Romania
-
Investigative Site
Bucharest, 030303, Romania
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
London, E1 1BB, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
Nottingham, NG7 2UH, United Kingdom
Conditions
Explore the condition pages connected to this study.